Microbial pathogenesis and type III interferons

Cytokine and Growth Factor Reviews

Volumn 29, Issue , 2016, Pages 45-51

  Cohen, Taylor S ^a   Parker, Dane ^b  

^a MEDIMMUNE   (United States)

^b Columbia University ^*  (United States)

Author keywords

Bacteria; Influenza; Interferon; Microbial pathogenesis; Superinfection; Type III IFN

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLUENZA VACCINE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR BETA; INTERLEUKIN 17; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSCRIPTION FACTOR ZEB1; INTERLEUKIN DERIVATIVE;

BACTERIAL CLEARANCE; BACTERIAL INFECTION; BACTERIAL SUPERINFECTION; BORRELIA BURGDORFERI; CHRONIC HEPATITIS C; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA POLYMORPHISM; ENTEROCOCCUS FAECALIS; GENE INDUCTION; HEPATITIS C; HOST RESISTANCE; IMMUNOLOGICAL TOLERANCE; INFLUENZA; INNATE IMMUNITY; INTERFERON INDUCTION; LACTOCOCCUS LACTIS; LISTERIA MONOCYTOGENES; MICROBIAL PATHOGENESIS; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SHORT SURVEY; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIA; SUPERINFECTION; VIRUS INFECTION; ANIMAL; HUMAN; IMMUNOLOGY;

ANIMALS; BACTERIAL INFECTIONS; HUMANS; IMMUNITY, INNATE; INTERLEUKINS; SIGNAL TRANSDUCTION; VIRUS DISEASES;

EID: 84960533428     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2016.02.005     Document Type: Short Survey

References (85)

1. World Health Organization Health Statistics and Information Department-Global Burden of Disease 2004 Update: Selected figures and tables (2004).
2. World Health Organization Antimicrobial Resistance-Global Report on Surveillance (2014).
3. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003, 4:63-68.
4. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003, 4:69-77.
5. Prokunina-Olsson L., Muchmore B., Tang W., Pfeiffer R.M., Park H., Dickensheets H., et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 2013, 45:164-171.
6. Hamming O.J., Terczynska-Dyla E., Vieyres G., Dijkman R., Jorgensen S.E., Akhtar H., et al. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 2013, 32:3055-3065.
7. Gad H.H., Dellgren C., Hamming O.J., Vends S., Paludan S.R., Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J. Biol. Chem. 2009, 284:20869-20875.
8. Sabat R. IL-10 family of cytokines. Cytokine Growth Factor Rev. 2010, 21:315-324.
9. Ank N., Iversen M.B., Bartholdy C., Staeheli P., Hartmann R., Jensen U.B., et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J. Immunol. 2008, 180:2474-2485.
10. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., Paludan S.R. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 2006, 80:4501-4509.
11. Durbin R.K., Kotenko S.V., Durbin J.E. Interferon induction and function at the mucosal surface. Immunol. Rev. 2013, 255:25-39.
12. Woodward J.J., Iavarone A.T., Portnoy D.A. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 2010, 328:1703-1705.
13. Gonzalez-Navajas J.M., Lee J., David M., Raz E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 2012, 12:125-135.
14. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2013, 14:36-49.
15. Sun L., Wu J., Du F., Chen X., Chen Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791.
16. Odendall C., Dixit E., Stavru F., Bierne H., Franz K.M., Durbin A.F., et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat. Immunol. 2014, 15:717-726.
17. Zhang X., Brann T.W., Zhou M., Yang J., Oguariri R.M., Lidie K.B., et al. Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN. J. Immunol. 2011, 186:4541-4545.
18. Miknis Z.J., Magracheva E., Li W., Zdanov A., Kotenko S.V., Wlodawer A. Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferon-lambdaR1. J. Mol. Biol. 2010, 404:650-664.
19. Hernandez P.P., Mahlakoiv T., Yang I., Schwierzeck V., Nguyen N., Guendel F., et al. Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat. Immunol. 2015, 16:698-707.
20. Jordan W.J., Eskdale J., Boniotto M., Rodia M., Kellner D., Gallagher G. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun. 2007, 8:13-20.
21. Dumoutier L., Tounsi A., Michiels T., Sommereyns C., Kotenko S.V., Renauld J.C. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J. Biol. Chem. 2004, 279:32269-32274.
22. Cohen T.S., Prince A.S. Bacterial pathogens activate a common inflammatory pathway through IFNlambda regulation of PDCD4. PLoS Pathog. 2013, 9:e1003682.
23. Doyle S.E., Schreckhise H., Khuu-Duong K., Henderson K., Rosler R., Storey H., et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006, 44:896-906.
24. Ioannidis I., Ye F., McNally B., Willette M., Flano E. Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J. Virol. 2013, 87:3261-3270.
25. Sommereyns C., Paul S., Staeheli P., Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008, 4:e1000017.
26. Blazek K., Eames H.L., Weiss M., Byrne A.J., Perocheau D., Pease J.E., et al. IFN-lambda resolves inflammation via suppression of neutrophil infiltration and IL-1beta production. J. Exp. Med. 2015, 212:845-853.
27. Mahlakoiv T., Hernandez P., Gronke K., Diefenbach A., Staeheli P. Leukocyte-derived IFN-alpha/beta and epithelial IFN-lambda constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog. 2015, 11:e1004782.
28. Meager A., Visvalingam K., Dilger P., Bryan D., Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005, 31:109-118.
29. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E.S., Kotenko S.V., MacDonald M.R., et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131:1887-1898.
30. Zhou Z., Hamming O.J., Ank N., Paludan S.R., Nielsen A.L., Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 2007, 81:7749-7758.
31. Bolen C.R., Ding S., Robek M.D., Kleinstein S.H. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 2014, 59:1262-1272.
32. Jilg N., Lin W., Hong J., Schaefer E.A., Wolski D., Meixong J., et al. Kinetic differences in the induction of interferon stimulated genes by interferon-alpha and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 2014, 59:1250-1261.
33. Jewell N.A., Cline T., Mertz S.E., Smirnov S.V., Flano E., Schindler C., et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J. Virol. 2010, 84:11515-11522.
34. Maher S.G., Sheikh F., Scarzello A.J., Romero-Weaver A.L., Baker D.P., Donnelly R.P., et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol. Ther. 2008, 7:1109-1115.
35. Pulverer J.E., Rand U., Lienenklaus S., Kugel D., Zietara N., Kochs G., et al. Temporal and spatial resolution of type I and III interferon responses in vivo. J. Virol. 2010, 84:8626-8638.
36. Ioannidis I., McNally B., Willette M., Peeples M.E., Chaussabel D., Durbin J.E., et al. Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection. J. Virol. 2012, 86:5422-5436.
37. Iversen M.B., Ank N., Melchjorsen J., Paludan S.R. Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs. J. Virol. 2010, 84:4579-4586.
38. Griffiths S.J., Koegl M., Boutell C., Zenner H.L., Crump C.M., Pica F., et al. A systematic analysis of host factors reveals a Med23-interferon-lambda regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog. 2013, 9:e1003514.
39. Swider A., Siegel R., Eskdale J., Gallagher G. Regulation of interferon lambda-1 (IFNL1/IFN-lambda1/IL-29) expression in human colon epithelial cells. Cytokine 2014, 65:17-23.
40. Suppiah V., Gaudieri S., Armstrong N.J., O'Connor K.S., Berg T., Weltman M., et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med. 2011, 8:e1001092.
41. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
42. Zhang A.M., Ma K., Song Y., Wang B., Feng Y., Liu L., et al. Genetic polymorphisms of the IFNlambda genes are associated with biochemical features in Han Chinese with HCV infection from Yunnan Province, China. Infect. Genet. Evol. 2014, 21:161-165.
43. Bibert S., Roger T., Calandra T., Bochud M., Cerny A., Semmo N., et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J. Exp. Med. 2013, 210:1109-1116.
44. Susser S., Herrmann E., Lange C., Hamdi N., Muller T., Berg T., et al. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS One 2014, 9:e112592.
45. Crow Y.J., Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat. Rev. Immunol. 2015, 15:429-440.
46. Brehm A., Liu Y., Sheikh A., Marrero B., Omoyinmi E., Zhou Q., et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J. Clin. Invest. 2015, 125:4196-4211.
47. Crow Y.J. Type I interferonopathies: a novel set of inborn errors of immunity. Ann. N.Y. Acad. Sci. 2011, 1238:91-98.
48. Liu Y., Jesus A.A., Marrero B., Yang D., Ramsey S.E., Montealegre Sanchez G.A., et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 2014, 371:507-518.
49. Koch S., Finotto S. Role of interferon-lambda in allergic asthma. J. Innate Immun. 2015, 7:224-230.
50. Miller E.K., Hernandez J.Z., Wimmenauer V., Shepherd B.E., Hijano D., Libster R., et al. A mechanistic role for type III IFN-lambda1 in asthma exacerbations mediated by human rhinoviruses. Am. J. Res. Crit. Care Med. 2012, 185:508-516.
51. Lazear H.M., Nice T.J., Diamond M.S. Interferon-lambda: immune functions at barrier surfaces and beyond. Immunity 2015, 43:15-28.
52. Crotta S., Davidson S., Mahlakoiv T., Desmet C.J., Buckwalter M.R., Albert M.L., et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog. 2013, 9:e1003773.
53. Mordstein M., Kochs G., Dumoutier L., Renauld J.C., Paludan S.R., Klucher K., et al. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 2008, 4:e1000151.
54. Nice T.J., Baldridge M.T., McCune B.T., Norman J.M., Lazear H.M., Artyomov M., et al. Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science 2015, 347:269-273.
55. Muir A.J., Arora S., Everson G., Flisiak R., George J., Ghalib R., et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J. Hepatol. 2014, 61:1238-1246.
56. Pietila T.E., Latvala S., Osterlund P., Julkunen I. Inhibition of dynamin-dependent endocytosis interferes with type III IFN expression in bacteria-infected human monocyte-derived DCs. J. Leukoc. Biol. 2010, 88:665-674.
57. Lebreton A., Lakisic G., Job V., Fritsch L., Tham T.N., Camejo A., et al. A bacterial protein targets the BAHD1 chromatin complex to stimulate type III interferon response. Science 2011, 331:1319-1321.
58. Bierne H., Travier L., Mahlakoiv T., Tailleux L., Subtil A., Lebreton A., et al. Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta. PLoS One 2012, 7:e39080.
59. Dhariwala M.O., Anderson D.M. Bacterial programming of host responses: coordination between type I interferon and cell death. Front. Microbiol. 2014, 5:545.
60. Robinson N., McComb S., Mulligan R., Dudani R., Krishnan L., Sad S. Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat. Immunol. 2012, 13:954-962.
61. Travar M., Vucic M., Petkovic M. Interferon lambda-2 levels in sputum of patients with pulmonary Mycobacterium tuberculosis infection. Scand. J. Immunol. 2014, 80:43-49.
62. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
63. Cervantes J.L., La Vake C.J., Weinerman B., Luu S., O'Connell C., Verardi P.H., et al. Human TLR8 is activated upon recognition of Borrelia burgdorferi RNA in the phagosome of human monocytes. J. Leukoc. Biol. 2013, 94:1231-1241.
64. Love A.C., Schwartz I., Petzke M.M. Borrelia burgdorferi RNA induces type I and III interferons via Toll-like receptor 7 and contributes to production of NF-kappaB-dependent cytokines. Infect. Immun. 2014, 82:2405-2416.
65. Krupna-Gaylord M.A., Liveris D., Love A.C., Wormser G.P., Schwartz I., Petzke M.M. Induction of type I and type III interferons by Borrelia burgdorferi correlates with pathogenesis and requires linear plasmid 36. PLoS One 2014, 9:e100174.
66. Parker D., Prince A. Staphylococcus aureus induces type I IFN signaling in dendritic cells via TLR9. J. Immunol. 2012, 189:4040-4046.
67. Parker D., Planet P.J., Soong G., Narechania A., Prince A. Induction of type I interferon signaling determines the relative pathogenicity of Staphylococcus aureus strains. PLoS Pathog. 2014, 10:e1003951.
68. Parker D., Cohen T.S., Alhede M., Harfenist B.S., Martin F.J., Prince A. Induction of type I interferon signaling by Pseudomonas aeruginosa is diminished in cystic fibrosis epithelial cells. Am. J. Respir. Cell Mol. Biol. 2012, 46:6-13.
69. Hendricks M.R., Lashua L.P., Fischer D.K., Flitter B.A., Eichinger K.M., Durbin J.E., et al. Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity. Proc. Natl. Acad. Sci. U. S. A. 2016, 113(6):1642-1647.
70. Jounai K., Ikado K., Sugimura T., Ano Y., Braun J., Fujiwara D. Spherical lactic acid bacteria activate plasmacytoid dendritic cells immunomodulatory function via TLR9-dependent crosstalk with myeloid dendritic cells. PLoS One 2012, 7:e32588.
71. McCullers J.A. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat. Rev. Microbiol. 2014, 12:252-262.
72. Rynda-Apple A., Robinson K.M., Alcorn J.F. Influenza and bacterial superinfection: illuminating the immunologic mechanisms of disease. Infect. Immun. 2015, 83:3764-3770.
73. Morens D.M., Taubenberger J.K., Fauci A.S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 2008, 198:962-970.
74. Metersky M.L., Masterton R.G., Lode H., File T.M., Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int. J. Infect. Dis. 2012, 16:e321-31.
75. Adams W.G., Deaver K.A., Cochi S.L., Plikaytis B.D., Zell E.R., Broome C.V., et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993, 269:221-226.
76. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 2003, 348:1737-1746.
77. Sun K., Metzger D.W. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat. Med. 2008, 14:558-564.
78. Shahangian A., Chow E.K., Tian X., Kang J.R., Ghaffari A., Liu S.Y., et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J. Clin. Invest. 2009, 119:1910-1920.
79. Lee B., Robinson K.M., McHugh K.J., Scheller E.V., Mandalapu S., Chen C., et al. Influenza-induced type I interferon enhances susceptibility to gram-negative and gram-positive bacterial pneumonia in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015, 309:L158-67.
80. Nakamura S., Davis K.M., Weiser J.N. Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J. Clin. Invest. 2011, 121:3657-3665.
81. Li W., Moltedo B., Moran T.M. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J. Virol. 2012, 86:12304-12312.
82. Robinson K.M., Lee B., Scheller E.V., Mandalapu S., Enelow R.I., Kolls J.K., et al. The role of IL-27 in susceptibility to post-influenza Staphylococcus aureus pneumonia. Respir. Res. 2015, 16. 10-015-0168-8.
83. Mina M.J., McCullers J.A., Klugman K.P. Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice. mBio 2014, 5. e01040-13.
84. Tarabichi Y., Li K., Hu S., Nguyen C., Wang X., Elashoff D., et al. The administration of intranasal live attenuated influenza vaccine induces changes in the nasal microbiota and nasal epithelium gene expression profiles. Microbiome 2015, 3:74.
85. Planet P.J., Parker D., Cohen T.S., Smith H., Leon J.D., Ryan C., et al. Interferon-lambda restructures the nasal microbiome and increases susceptibility to Staphylococcus aureus superinfection. mBio 2016, 7. e01939-115.